Skip to content

Just another WordPress site

Monthly Archives: February 2017

Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Posted byJulianne TwiningFebruary 9, 2017February 11, 2019Posted inUncategorizedLeave a comment on Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Search for:

Recent Posts

BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source
BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity
PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People with High Frequency Basal Cell Carcinoma
BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma
BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

Recent Comments

Archives

January 2020
December 2019
November 2019
October 2019
September 2019
June 2019
May 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
June 2018
May 2018
April 2018
March 2018
January 2018
November 2017
October 2017
September 2017
July 2017
April 2017
February 2017
January 2017
December 2016

Categories

investor
partner
Uncategorized

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

bridgebiowp, Proudly powered by WordPress.